Neurology

Your Article Summary

See Latest Articles

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation
European Journal of Neurology, 06/24/09

Sellebjerg F et al. - The authors identify IFI27, CCL2 and CXCL10 as sensitive biomarkers for the response to IFN-beta. The expression of these markers adequately reflects bioactivity of IFN-beta as documented by the decreased induction in low NAb-positive patients and the lost induction in patients with moderate/high NAb levels.

Today in Basic Science/Genetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Archives of Neurology, 10/14/09

Changes in Hippocampal Metabolites After Effective Treatment for Fibromyalgia: A Case Study
The Clinical Journal of Pain, 10/20/09

Neurological symptoms in patients with biopsy proven celiac disease
Movement Disorders, 11/03/09

See All of Basic Science/Genetics

Today in Demyelinating Disorders...keeping you current

Receive free subspecialty "5-minute updates" via email

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
The Lancet, 11/03/09

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09

See All of Demyelinating Disorders